Difference between revisions of "LINC02859"
(Created page with "LINC02859,a long non-coding RNA, function as anti-oncogene and also plays an important role in GC tumorigenesis.<ref name="ref1" /> ==Annotated Information== ===Name===...") |
(→Expression) |
||
| Line 18: | Line 18: | ||
LINC02859 can regulate PI3K-Akt-mTOR signaling pathway and change the GC development progression in vivo and in vitro.<ref name="ref1" /> | LINC02859 can regulate PI3K-Akt-mTOR signaling pathway and change the GC development progression in vivo and in vitro.<ref name="ref1" /> | ||
===Expression=== | ===Expression=== | ||
| − | [[File:LINC02859-exp.jpg|thumb| | + | [[File:LINC02859-exp.jpg|thumb|550px|LINC02859 overexpression can inhibit the GC tumorigenesis in vivo.<ref name="ref1"/>]] |
LINC02859 was significantly downregulated in gastric cancer (GC) tissues specimen, GC cell lines, and associated with the GC patients tumor, node, and metastasis (TNM) stage and degree of differentiation (P < 0.05).<ref name="ref1"/> | LINC02859 was significantly downregulated in gastric cancer (GC) tissues specimen, GC cell lines, and associated with the GC patients tumor, node, and metastasis (TNM) stage and degree of differentiation (P < 0.05).<ref name="ref1"/> | ||
LINC02859 overexpression can inhibit the GC tumorigenesis in vivo.<ref name="ref1"/> | LINC02859 overexpression can inhibit the GC tumorigenesis in vivo.<ref name="ref1"/> | ||
| + | |||
===Diseases=== | ===Diseases=== | ||
Gastric cancer (GC) <ref name="ref1"/> | Gastric cancer (GC) <ref name="ref1"/> | ||
Latest revision as of 09:07, 20 February 2021
LINC02859,a long non-coding RNA, function as anti-oncogene and also plays an important role in GC tumorigenesis.[1]
Contents
Annotated Information
Name
Approved symbol:LINC02859
HGNC ID:54399
Approved name:long intergenic non-protein coding RNA 2859
Alias symbol:LncRNA-LOC101928316
RefSeq ID:XR_001748478
Characteristics
location:11p15.2
Function
LINC02859 overexpression can significantly inhibit SGC-7901 cell migration, invasion, and proliferation (P<0.05).[1]
Regulation
LINC02859 can regulate PI3K-Akt-mTOR signaling pathway and change the GC development progression in vivo and in vitro.[1]
Expression
LINC02859 was significantly downregulated in gastric cancer (GC) tissues specimen, GC cell lines, and associated with the GC patients tumor, node, and metastasis (TNM) stage and degree of differentiation (P < 0.05).[1] LINC02859 overexpression can inhibit the GC tumorigenesis in vivo.[1]
Diseases
Gastric cancer (GC) [1]
Labs working on this lncRNA
- Department of Toxicology, School of Public Health, Lanzhou University, Lanzhou, China.[1]
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, China.[1]
- Gansu Wuwei Tumor Hospital, Wuwei, China.[1]
- Department of Oncology, Jiangsu Cancer Hospital, Nanjing, China.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Li C, Liang G, Yang S, Sui J, Wu W, Xu S, Ye Y, Shen B, Zhang X, Zhang Y. LncRNA-LOC101928316 contributes to gastric cancer progression through regulating PI3K-Akt-mTOR signaling pathway. Cancer Med. 2019 Aug;8(9):4428-4440. doi: 10.1002/cam4.2165. Epub 2019 Jun 17. PMID: 31207155; PMCID: PMC6675725.
